Researchers examine trends in prescription opioid use for non-cancer pain

NewsGuard 100/100 Score

A review of more than 4 million insured patients with private coverage and Medicaid, published in the The Journal of Pain showed that rates of opioid use did not differ widely between non-cancer pain conditions but there were higher rates of opioid use among Medicaid patients.

In this study, researchers examined general trends in prescription opioid use in patients covered by HealthCore private insurance and Arkansas Medicaid. They sought to determine if increases in opioids use are limited to particular non-cancer pain (NPC) conditions and how patterns of use differ between NCP conditions and among those with multiple pain conditions.

Trends reported in the study suggest an increased tendency to prescribe long-term opioid therapy, especially for those with multiple pain conditions, which also have been associated with greater psychopathology than single pain conditions. The presence of a comorbid mental disorder may predict opioid use among individuals with chronic pain.

The authors concluded that higher rates of opioid use in the Arkansas Medicaid patients likely reflects the greater disability and disease burden of this population, and added it's also possible this disadvantaged population has less access to nonopioid rehabilitative therapy for NCP compared with privately insured individuals.

http://www.ampainsoc.org/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels